Licensed Practical Nurse in Pendleton, OR Accepting Medicare

7 Licensed Practical Nurse nurses found. Showing 1 - 7

Anthony Christopher Bass, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 707 Sw 37th St, Pendleton, OR 97801 Phone: 541-276-3374    Fax: 541-276-5326

Kelli Ann Peterson, RN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 73265 Confederated Way, Pendleton, OR 97801 Phone: 541-966-9830

Ms. Cheri Kay Rosenberg, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 73265 Confederated Way, Pendleton, OR 97801 Phone: 541-966-9830    Fax: 541-278-7572

Ms. Stacey Marie Jones, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 73265 Confederated Way, Pendleton, OR 97801 Phone: 541-966-9830

Christina Mascak, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 73265 Confederated Way, Pendleton, OR 97801 Phone: 541-966-9830

Sheffie Dan Surber Jr., LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2575 Westgate Bldg 13, Pendleton, OR 97801 Phone: 541-429-8721    Fax: 541-429-8720

Fred H Thomas Iii, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 331 Se 2nd St, Pendleton, OR 97801 Phone: 541-889-9167    Fax: 541-889-7873

News Archive

FDA assigns new PDUFA date for Takeda's investigational type 2 diabetes therapy, alogliptin

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., today announced that the company received notification from the U.S. Food and Drug Administration (FDA) that its review of investigational type 2 diabetes therapy alogliptin, and thus the fixed-dose combination therapy alogliptin/pioglitazone, will be delayed.

Perrigo to settle patent litigation relating to Minoxidil foam

Perrigo Company today announced that it has agreed to settle its Hatch-Waxman litigation relating to Minoxidil foam brought by Stiefel Research Australia Pty. Ltd., a GSK Company. Under the terms of the settlement, Perrigo can launch in the U. S., a generic version of Men's Rogaine® Foam on March 1, 2012, or earlier under certain circumstances.

Viewpoints: Concerns that AIDS fight is losing steam; Pharmacy choice bill is praised; Texas sex-ed policies questioned

The considerable progress in recent years-;including the 22-fold increase in the number of people receiving anti-retroviral drugs between 2001-2010-;has been due to scientific breakthroughs and to civil society's efforts to keep AIDS on the political agenda. This is now changing.

Antimuscarinics only moderately effective for overactive bladder

A comprehensive review of oral antimuscarinics for the treatment of overactive bladder concludes that the efficacy of treatment is, at best, moderate.

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

Read more Medical News

› Verified 8 days ago